OTC Markets OTCPK - Delayed Quote USD

Novo Nordisk A/S (NONOF)

Compare

109.80

-2.20

(-1.96%)

At close: November 4 at 3:00 p.m. EST

Key Events

Advanced Chart

Loading Chart for NONOF

9/21 12:03 PM

DELL

Previous Close 112.00
Open 110.00
Bid 110.00 x 29200
Ask 111.40 x 41800
Day's Range 110.00 - 112.00
52 Week Range 93.80 - 149.55
Volume 200
Avg. Volume 38,907
Market Cap (intraday) 499.241B
Beta (5Y Monthly) 0.15
PE Ratio (TTM) 38.12
EPS (TTM) 2.88
Earnings Date Nov 6, 2024
Forward Dividend & Yield 1.45 (1.30%)
Ex-Dividend Date Aug 15, 2024
1y Target Est --

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

www.novonordisk.com

69,260

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Drug Manufacturers - General

Industry

Hims & Hers Health jumps on earnings. CFO talks GLP-1 influences.

IBD 50's No. 2 Stock, Hims & Hers, Smashes Estimates On 'Robust' Obesity Trajectory

Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat

Viking Therapeutics stock falling amid results for new GLP-1 pill

Wall Street Bulls Look Optimistic About Novo Nordisk (NVO): Should You Buy?

Danish town where weight-loss wonder drug Ozempic is made suffers from the highest rates of overweight children in Denmark

Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?

Global stocks lacklustre as investors scale back bets on Trump election win

Election Day, Fed decision, earnings: What to Watch

Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH

Novo Nordisk Says Wegovy Improved Patients’ Liver Disease

Hims & Hers Health jumps on earnings. CFO talks GLP-1 influences.

Hims & Hers Health (HIMS) shares jumped in extended trading after the company reported better than expected third quarter revenue and raised its outlook. The telehealth company swung to a profit, helped by a tax benefit and strong demand for GLP-1 weight-loss drugs. In an interview on Market Domination Overtime, Hims & Hers Health CFO Yemi Okupe speaks with anchors Julie Hyman and Josh Lipton about the quarter. "We saw revenue up 77% year-over-year to north of 4$00 million. Simultaneously, we're also seeing very strong EBITDA margins at north of 13%," Okupe says. "Additionally, at the end of the quarter, we also saw 2 million consumers on the platform, of which 1 million were benefiting from a personalized solution. And so really, the strong results that we're seeing in the third quarter are a reflection of us executing across the strategy that we've held for the past couple of years." Okupe also addresses a possible headwind for the company, that Eli Lilly (LLY)'s and Novo Nordisk (NVO)'s weight-loss drugs are coming off the FDA's (Food and Drug Administration) shortage lists. But Okupe says it's not a concern right now, but acknowledges the shortages will come to an end."In our view, we do still see that the medications are on on shortage. And what we do see on our platform. And this is the benefit of being a consumer oriented platform, is that we hear feedback directly from consumers and what consumers are telling us, you know resoundingly, is that they are struggling to get access to name-brand GLP-1 medications over the last two months," according to Okupe. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. This post was written by Rachel Sherman.

01:26
Viking Therapeutics stock falling amid results for new GLP-1 pill

Yahoo Finance 7 hrs ago
00:57
Election Day, Fed decision, earnings: What to Watch

Yahoo Finance 3d ago

Trailing total returns as of 2024-11-04, which may include dividends or other distributions. Benchmark is

OMX Copenhagen 25 Index

YTD Return

NONOF

8.32%

OMX Copenhagen 25 Index

5.01%

1-Year Return

NONOF

13.73%

OMX Copenhagen 25 Index

16.98%

3-Year Return

NONOF

97.55%

OMX Copenhagen 25 Index

3.22%

5-Year Return

NONOF

314.42%

OMX Copenhagen 25 Index

63.05%

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

NONOF

Novo Nordisk A/S

109.80

-1.96%

Mkt Cap 499.241B